Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Simple item page
dc.contributor.affiliationCentre de Traitement Ambulatoire, Brazzaville, Republic of the Congo.
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
dc.contributor.affiliationInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
dc.contributor.affiliationInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
dc.contributor.affiliationNewlands Clinic, Harare, Zimbabwe.
dc.contributor.affiliationCentre National de Transfusion Sanguine, Abidjan, Côte d'Ivoire.
dc.contributor.affiliationCenter for AIDS Research, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
dc.contributor.affiliationCentre de Traitement Ambulatoire, Pointe Noire, Republic of the Congo.
dc.contributor.affiliationPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
dc.contributor.affiliationLighthouse Trust, Lilongwe, Malawi.
dc.contributor.affiliationCentre de Prise en Charge, de Recherche et de Formation, Abidjan, Côte d'Ivoire.
dc.contributor.affiliationKwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa.
dc.contributor.affiliationFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
dc.contributor.affiliationPublic Health Department, Regional Referral Hospital, Masaka, Uganda.
dc.contributor.affiliationCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
dc.contributor.affiliationInfectious Diseases Institute, Makerere University, Kampala, Uganda.
dc.contributor.affiliationHôpital Jamot, Yaoundé and Regional Hospital, Limbé, Cameroon.
dc.contributor.affiliationAIDS Healthcare Foundation Uganda Cares, Masaka, Uganda.
dc.contributor.affiliationCentre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
dc.contributor.affiliationDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorLoosli T
dc.contributor.authorMoore CB
dc.contributor.authorBuzaalirwa L
dc.contributor.authorByakwaga H
dc.contributor.authorÇelikağ İ
dc.contributor.authorChimbetete C
dc.contributor.authorEbasone PV
dc.contributor.authorGiandhari J
dc.contributor.authorHan N
dc.contributor.authorHuwa J
dc.contributor.authorKasozi C
dc.contributor.authorMafoua A
dc.contributor.authorMessou E
dc.contributor.authorMinga A
dc.contributor.authorMuula G
dc.contributor.authorMuyindike W
dc.contributor.authorNdala ACM
dc.contributor.authorSauermann M
dc.contributor.authorSemeere A
dc.contributor.authorSingh L
dc.contributor.authorKouyos RD
dc.contributor.authorLessells R
dc.contributor.authorEgger M
dc.date.accessioned2025-05-23T11:40:28Z
dc.date.issued2025-May-20
dc.description.abstractDolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
dc.identifier.doi10.1093/cid/ciaf204
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10190
dc.sourceClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.titleDrug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Files

Collections

Published